According to a study published in BMC Womens Health journal, elagolix (a gonadotropin-releasing hormone receptor antagonist) effectively reduced non-menstrual pelvic pain (NMPP) and dysmenorrhea (menstrual cramps) and improved health-related quality of life (HRQoL) across subgroups of females with different baseline features, encompassing demographic categories as well as a broad range of clinical variables that characterize endometriosis people.

Evidences have suggested the use of elagolix to significantly reduce NMPP and dysmenorrhea in women with endometriosis pain. The data from this study were gathered from two studies (Elaris Endometriosis [EM]-I and EM-II) in which elagolix dosed at 150 mg taken once and 200 mg taken twice per day were assessed. Overall, more than 1600 females in the age group of 18 to 49 years were evaluated to determine the efficacy of elagolix and HRQoL in women with numerous baseline characteristics.

Out of the total females, 1285 (76.2%) completed the studies. The number of females with clinically significant decreases in dysmenorrhea and NMPP were generally steady by subgroup. Subgroup analysis revealed notable outcomes for dysmenorrhea response in pain-relieving medicine usage and history of pregnancy subgroups, and similarly for NMPP response in the NMPP score and history of pregnancy subgroups at the starting point.

Nearly all female subgroups taking elagolix 200 mg and most subgroups with elagolix 150 mg had noteworthy pain decrease by the end of 3^rd month. In addition, an improvement in each area of the Endometriosis Health Profile-30 (EHP-30) was observed in females across subgroups. Thus, elagolix offers a clinically significant decline in dysmenorrhea and NMPP, as well as improvement in quality of life in females with moderate-to-severe endometriosis-linked pain.